1. |
If
sales of common stock by AGLR are reported, the purchase price per
share
and the market price per share at the date of the agreement of sale
and
the aggregate amount of common stock outstanding during the Authorization
Period;
|
2. |
The
total number of shares of AGLR's common stock issued or issuable
pursuant
to options granted during the quarter under employee benefit plans
and
dividend reinvestment plans including any employee benefit plans
or
dividend reinvestment plans hereafter adopted and the total number
of
shares of AGLR’s common stock issued or
issuable pursuant to options outstanding during the Authorization
Period;
|
3. |
If
AGLR’s common stock has been transferred to a seller of securities of
a
company being acquired, the number of shares so issued, the value
per
share and whether the shares are restricted in the hands of the
acquirer;
|
4. |
If
a guarantee is issued during the quarter, the name of the guarantor,
the
name of the beneficiary of the guarantee and the amount, terms and
purpose
of the guarantee, and the total amount of guarantees issued and
outstanding during the Authorization
Period;
|
5. |
The
amount and terms of any financings consummated by Atlanta Gas Light
Company (”AGLC”), Chattanooga Gas Company (“CGC”), Virginia Natural Gas
(“VNG”),
Pivotal
Utility Holdings, Inc., formerly known as NUI Utilities, Inc. ("Pivotal")
or Virginia Gas Distribution Company ("VGDC") that are not exempt
under
rule 52, and the total amount of such financings outstanding of
each of
AGLC, CGC, VNG, Pivotal and VGDC during the Authorization Period.
|
6. |
If
any of AGLR's subsidiaries (including the NUI Group companies) are
Variable Interest Entities ("VIEs") as that term is used in FASB
Interpretation 46R, Consolidation of Variable Interest Entities,
provide a
description of any financing transactions conducted during the reporting
period that were used to fund such
VIEs;
|
7. |
If
any financing proceeds are used for VIEs, a description of the accounting
for such transaction under FASB Interpretation
46R;
|
8. |
A
list of U-6B-2 forms filed with the Commission during the quarter,
including the name of the filing entity and the date of
filing;
|
9. |
Consolidated
balance sheets as of the end of the quarter and separate balance
sheets as
of the end of the quarter for each company, including AGL Resources,
that
has engaged in utility money pool transactions during the
quarter;
|
10. |
Future
registration statements filed under the 1933 Act with respect to
securities issuances that are the subject of the Application will
be filed
or incorporated by reference as a part of this filing pursuant to
rule 24
|
11. |
A
table showing, as of the end of the quarter, the dollar and percentage
components of the capital structure of AGL Resources on a consolidated
basis, and each of AGLC, CGC, VNG, Pivotal and VGDC;
|
12. |
A
retained earnings analysis of AGL Resources on a consolidated basis
and
for each of AGLC, CGC, VNG, Pivotal and VGDC detailing gross earnings,
goodwill amortization, dividends paid out of capital surplus, and
the
resulting capital account balances at the end of the quarter;
|
13. |
Certain
financial information regarding AGLC, CGC, VNG, VGDC, Pivotal,
Elizabethtown Gas, Elkton Gas and Florida City Gas as follows: revenues,
cost of goods sold, operating income, interest, taxes, amortization,
net
income, fixed assets, current assets and total
assets.
|
14. |
AGLR
will report on the progress of winding down and dissolving, merging
or
selling certain NUI Non-utility Subsidiaries identified in Exhibit
J-1 of
this Application.
|
Exhibit
|
Description
|
Note
|
1
|
Guarantees
Issued
|
*
|
2
|
Financings
Not Exempt under Rule 52
|
|
3
|
Information
Regarding Variable Interest Entities
|
|
4
|
Balance
Sheets of Subsidiaries Engaged in Utility Money Pool
Transactions
|
*
|
4.1
|
Balance
Sheets of Subsidiaries Engaged in Utility Money Pool
Transactions
|
*
|
5
|
Capital
Structure Table
|
*
|
6
|
Common
Shareholders' Equity Analysis
|
*
|
7
|
Other
Financial Information
|
*
|
*
|
Submitted
under request for confidential treatment pursuant to Rule 104
|